Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) gapped up before the market opened on Tuesday after Morgan Stanley raised their price target on the stock from $46.00 to $96.00. The stock had previously closed at $51.71, but opened at $54.63. Morgan Stanley currently has an overweight rating on the stock. Akero Therapeutics shares last traded at $55.10, with a volume of 920,635 shares changing hands.
Other equities analysts have also issued research reports about the stock. Citigroup lifted their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday. Canaccord Genuity Group boosted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, HC Wainwright increased their price objective on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $61.57.
Read Our Latest Report on Akero Therapeutics
Insider Activity at Akero Therapeutics
Institutional Investors Weigh In On Akero Therapeutics
Several hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. grew its stake in Akero Therapeutics by 15.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock valued at $8,141,000 after acquiring an additional 38,279 shares in the last quarter. FMR LLC grew its position in Akero Therapeutics by 732.1% during the third quarter. FMR LLC now owns 30,337 shares of the company’s stock valued at $870,000 after purchasing an additional 26,691 shares in the last quarter. SG Americas Securities LLC increased its stake in Akero Therapeutics by 4,022.1% in the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after buying an additional 583,486 shares during the period. Barclays PLC lifted its position in Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock worth $3,662,000 after buying an additional 71,652 shares in the last quarter. Finally, Propel Bio Management LLC lifted its position in Akero Therapeutics by 4.9% in the 3rd quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock worth $9,862,000 after buying an additional 15,977 shares in the last quarter.
Akero Therapeutics Stock Down 0.5 %
The business’s 50 day simple moving average is $28.90 and its 200-day simple moving average is $28.33. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company has a market cap of $3.59 billion, a price-to-earnings ratio of -13.73 and a beta of -0.19.
Akero Therapeutics (NASDAQ:AKRO – Get Free Report) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.
About Akero Therapeutics
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Recommended Stories
- Five stocks we like better than Akero Therapeutics
- How to Short a Stock in 5 Easy Steps
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is a support level?
- What Does the Future Hold for Eli Lilly?
- Why Are Stock Sectors Important to Successful Investing?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.